Severity: Warning
Message: file_get_contents(https://...@pubfacts.com&api_key=b8daa3ad693db53b1410957c26c9a51b4908&a=1): Failed to open stream: HTTP request failed! HTTP/1.1 429 Too Many Requests
Filename: helpers/my_audit_helper.php
Line Number: 176
Backtrace:
File: /var/www/html/application/helpers/my_audit_helper.php
Line: 176
Function: file_get_contents
File: /var/www/html/application/helpers/my_audit_helper.php
Line: 250
Function: simplexml_load_file_from_url
File: /var/www/html/application/helpers/my_audit_helper.php
Line: 3122
Function: getPubMedXML
File: /var/www/html/application/controllers/Detail.php
Line: 575
Function: pubMedSearch_Global
File: /var/www/html/application/controllers/Detail.php
Line: 489
Function: pubMedGetRelatedKeyword
File: /var/www/html/index.php
Line: 316
Function: require_once
We herein developed a transformable mixing-type material for reversible PEGylation of protein drugs using a supramolecular backbone polymer, that is, polyrotaxane possessing both amino groups and PEG chains (PEG-NH-PRX). We expected that PEG-NH-PRX provides amino groups to interact with protein drugs on demand because the mobility of amino groups in PEG-NH-PRX was high. In fact, PEG-NH-PRX formed complexes with protein drugs efficiently compared to PEGylated amino-dextran (PEG-NH-DEX), a control material fabricated with a macromolecular backbone polymer. Moreover, PEG-NH-PRX markedly improved the stability of antibodies and prolonged the hypoglycemic effects of insulin without loss of bioactivity, compared to PEG-NH-DEX. These findings suggest that the supramolecular material, PEG-NH-PRX, is a promising reversible PEGylation material for protein drugs compared to macromolecular materials.
Download full-text PDF |
Source |
---|---|
http://www.ncbi.nlm.nih.gov/pmc/articles/PMC8605344 | PMC |
http://dx.doi.org/10.1016/j.mtbio.2021.100160 | DOI Listing |
Enter search terms and have AI summaries delivered each week - change queries or unsubscribe any time!